End-Payors Ink $30M Novartis Exforge Deal

End-Payors Ink $30M Novartis Exforge Deal

Source Node: 1975781
By Nadia Dreid (February 23, 2023, 10:47 PM EST) — Novartis has reached another deal to shake off claims that it hatched an illegal deal with Par Pharmaceuticals to delay the release of a generic version of the blood pressure drug Exforge, this one with end payors for $30 million….

Time Stamp:

More from Law 360